Mineralys Therapeutics is a biopharmaceutical company developing medicines for diseases driven by dysregulated aldosterone. The company's lead product candidate is lorundrostat, a selective oral aldosterone synthase inhibitor designed to treat cardiorenal conditions including hypertension, chronic kidney disease, and obstructive sleep apnea, targeting large patient populations where existing treatments prove inadequate. Mineralys operates a development-stage model, outsourcing manufacturing to contract partners while funding operations through milestone payments and eventual royalties on net sales from its exclusive worldwide license of lorundrostat from Tanabe Pharma Corporation.